InsiderTrades

Form 4 for AMGN Amgen

Accepted 2023-05-09 00:00:00 ET · period of report 2023-05-05 · accession 0001127602-23-015043 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
2023-05-09 2023-05-05 AMGN Bradway Robert A COB, CEO, Pres, Dir F - Tax $231.89 -2,083 641.7K -0.3% -$483.0K

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2023-05-05 F D 2,083 $231.89 641,734 D — — (F2) These shares include 1,431 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. (F1) These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 4,143 RSUs which will vest on 5/5/2024; 8.898 RSUs which will vest in installments of 4,382 on 4/30/2024 and 4,516 on 4/30/2025; 13,781 RSUs which will vest in installments of 4,547 on 5/2/2024, 4,548 on 5/2/2025, and 4,686 on 5/2/2026; and 13,486 RSUs which will vest in two installments of 4,450 on 5/2/2025 and 5/2/2026, and 4,586 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.